BNP Paribas Arbitrage SA raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 26.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 91,473 shares of the company’s stock after purchasing an additional 19,103 shares during the quarter. BNP Paribas Arbitrage SA owned approximately 0.10% of Neurocrine Biosciences worth $5,605,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently modified their holdings of NBIX. The Manufacturers Life Insurance Company grew its stake in Neurocrine Biosciences by 7.8% in the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after purchasing an additional 193 shares in the last quarter. ARS Investment Partners LLC purchased a new position in Neurocrine Biosciences in the second quarter valued at about $207,000. Stephens Inc. AR purchased a new position in Neurocrine Biosciences in the second quarter valued at about $207,000. Ardsley Advisory Partners purchased a new position in Neurocrine Biosciences in the second quarter valued at about $230,000. Finally, Cubist Systematic Strategies LLC grew its stake in Neurocrine Biosciences by 151.5% in the second quarter. Cubist Systematic Strategies LLC now owns 5,301 shares of the company’s stock valued at $244,000 after purchasing an additional 3,193 shares in the last quarter.
A number of research analysts have commented on the company. BMO Capital Markets boosted their target price on Neurocrine Biosciences from $75.00 to $84.00 and gave the company an “outperform” rating in a research note on Friday, August 4th. Oppenheimer Holdings, Inc. boosted their target price on Neurocrine Biosciences from $70.00 to $85.00 and gave the company an “outperform” rating in a research note on Thursday, November 2nd. Piper Jaffray Companies set a $68.00 target price on Neurocrine Biosciences and gave the company a “buy” rating in a research note on Thursday, August 24th. Citigroup Inc. restated a “buy” rating and issued a $79.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Finally, Needham & Company LLC restated a “buy” rating and issued a $86.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. One investment analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. Neurocrine Biosciences presently has an average rating of “Buy” and an average target price of $78.88.
Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at $72.28 on Friday. Neurocrine Biosciences, Inc. has a 12-month low of $37.35 and a 12-month high of $75.98. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.36. The business had revenue of $60.77 million for the quarter, compared to analyst estimates of $29.38 million. During the same period in the prior year, the firm posted ($0.43) EPS. research analysts predict that Neurocrine Biosciences, Inc. will post -1.74 earnings per share for the current fiscal year.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.